drugset / Trial / NCT01650324
A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects
RandomizedSingle-groupTriple-blindTreatment
Summary
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of single oral doses of DBPR108 in healthy male subjects.
Timeline
- Start
- 2012-07
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DBPR108 | Small molecule | 25 mg | Oral |
| Subject | DBPR108 | Small molecule | 600 mg | Oral |